74 results about "Infarct size" patented technology

A method and apparatus for prevention and reduction of myocardial infarct size and / or expansion and heart remodeling by partial, controllable and reversible obstruction of the venous blood flow to the heart. As a result, the ventricular wall stress and dilation are reduced. Blood flow is maintained at a safe level for the duration of treatment. The apparatus consists of a catheter with an occlusion balloon and a control and monitoring system.

A method and apparatus for evaluating acute stroke patients and for determining whether a stroke patient will benefit from the use of thrombolysis therapy includes obtaining measurements of the cerebral blood flow and cerebral blood volume of the brain of a stroke patient, determining ischemic areas of the brain where the ischemic areas comprise the measurements of cerebral blood flow which are less than a first value and creating a penumbra-infarct map of the ischemic areas of the brain using the measurements. The infarct area corresponds to the area of the brain where cerebral blood volume is less than a second value. The penumbra area corresponds to the area of the brain where cerebral blood volume is greater than this second value. The method also includes determining a ratio of penumbra size to the total of penumbra size and infarct size. When the ratio is greater than a predetermined value, the stroke patient is a candidate for thrombolysis therapy.

A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and / or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.

A method and apparatus for evaluating acute stroke patients and for determining whether a stroke patient will benefit from the use of thrombolysis therapy includes obtaining measurements of the cerebral blood flow and cerebral blood volume of the brain of a stroke patient, determining ischemic areas of the brain where the ischemic areas comprise the measurements of cerebral blood flow which are less than a first value and creating a penumbra-infarct map of the ischemic areas of the brain using the measurements. The infarct area corresponds to the area of the brain where cerebral blood volume is less than a second value. The penumbra area corresponds to the area of the brain where cerebral blood volume is greater than this second dvalue. The method also includes determining a ratio of penumbra size to the total of penumbra size and infarct size. When the ratio is greater than a predetermined value, the stroke patient is a candidate for thrombolysis therapy.

This invention relates to a pharmaceutical composition for preventing and curing myocardium ischemia and reducing area of myocardial infarction, its pharmaceutical preparation and applications. The composition includes (a) levocarnitine or its derivatives, and (b) trimetazidine or its medicative salts. The quantity of levocarnitine or its derivatives, and trimetazidine or its medicative salts in the composition is effective amount for treating myocardial ischemia and reducing the area of myocardial infarction.

The present invention is related to benzothiophen-2-carbonylguanidine derivatives, a preparation method thereof, and pharmaceutical compositions containing the same. The derivatives have potent inhibitory effect on the sodium / hydrogen exchanger NHE-I, improve the functional recovery of ischemia / reperfusion-induced heart injury in isolated ischemic heart models, and significantly reduce the myocardiac infarct size in in vivo ischemic animal models, thereby showing excellent cardioprotective effects. Also, the derivatives are protective of both neuronal cells and the brain as proven by their protective effects on neuronal cells from necrosis and apoptosis and by their ability to significantly reduce cerebral infarct sizes in in vivo ischemic brain models. The derivatives can be effectively used for the prevention and treatment of ischemic heart diseases such as myocardiac infarction, arrhythmia, angina pectoris and the like, and cerebrovascular diseases such as cerebral stroke and be used as cardioprotective agents to the patients undergoing reperfusion therapy including chemicals such as thrombolytic agents, or surgery such as coronary artery bypass and percutaneous transluminal coronary angioplasty.

Methods of preventing sustained monomorphic ventricular tachycardia following myocardial ischemia, decreasing infarct size and / or decreasing the incidence and / or maximum intrinsic rate of very rapid ventricular triplets following myocardial ischemia is disclosed. The methods involve administering an effective amount of a composition that inhibits substantial loss of beta-adrenergic receptor kinase (β-ARK) activity and / or β-ARK expression.

This invention relates to a pharmaceutical composition for preventing and curing myocardium ischemia and reducing area of myocardial infarction, its pharmaceutical preparation and applications. The composition includes (a) levocarnitine or its derivatives, and (b) trimetazidine or its medicative salts. The quantity of levocarnitine or its derivatives, and trimetazidine or its medicative salts in the composition is effective amount for treating myocardial ischemia and reducing the area of myocardial infarction.

The purpose of the present invention is, when treating circulatory disease such as acute myocardial infarction, to correct a reduction in myocardial contractility and thereby prevent arrhythmia and the like, as well as to reduce infarct size. Provided is a neurostimulation device having a stimulus application part configured so as to apply a stimulus to a cervical or thoracic vagus nerve portion in a human or an animal, and a stimulus regulation part configured so as to regulate the quantity of stimulus applied from the stimulus application part to the vagus nerve portion. The stimulus regulation part establishes a quantity of stimulus that is less than a value at which adverse effects would be produced, determines the heart rate and R wave interval of the human or animal, and controls the quantity of stimulus on the basis of these determinations.

The present invention describes a particle secreted by mesenchymal stem cells and comprising at least one biological characteristic of mesenchymal stem cells. The biological properties may comprise biological activities of mesenchymal stem cell conditioned medium (MSC-CM), such as cardioprotection or reduction in infarct size. The particles may comprise vesicles or exosomes.